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E-mail: sebastian.kuegler@med.uni-goettingen.deGene therapy in its current design is an irreversible process. It
cannot be stopped in case of unwanted side effects, nor can
expression levels of therapeutics be adjusted to individual pa-
tient’s needs. Thus, the Gene-Switch (GS) system for pharma-
cologically regulable neurotrophic factor expression was estab-
lished for treatment of parkinsonian patients. Mifepristone,
the synthetic steroid used to control transgene expression of
the GS vector, is an approved clinical drug. However, pharma-
cokinetics and -dynamics of mifepristone vary considerably be-
tween different experimental animal species and depend on age
and gender. In humans, but not in any other species, mifepris-
tone binds to a high-affinity plasma carrier protein. We now
demonstrate that the formulation of mifepristone can have
robust impact on its ability to activate the GS system. Further-
more, we show that a pharmacological booster, ritonavir (Rtv),
robustly enhances the pharmacological effect of mifepristone,
and allows it to overcome gender- and species-specific pharma-
cokinetic and -dynamic issues. Most importantly, we demon-
strate that the GS vector can be efficiently controlled by mife-
pristone in the presence of its human plasma carrier protein,
a1-acid glycoprotein, in a “humanized” rat model. Thus, we
have substantially improved the applicability of the GS vector
toward therapeutic use in patients.
INTRODUCTION
Tight control over expression of neurotrophic factors, as treatments
for devastating neurological conditions such as Parkinson’s disease
(PD) and Alzheimer’s disease, can be considered essential to their
clinical success: pharmacologically controlled gene therapy may allow
us to enroll patients with much less advanced pathology into clinical
trials, allowing us to revert neurodegenerative conditions at times
where restoration is still possible.1 Furthermore, transduction of
larger brain areas may become possible without having to fear side ef-
fects as they have been reported for continuous expression of neuro-
trophic factor GDNF,2,3 and intermitted expression of neurotrophic
factors may prevent saturation effects of receptors and signaling path-
ways, thus allowing for better therapeutic efficacy.4 Several regulable
gene therapy system have been developed, which allow us to place
transgene expression under control of a pharmacological compound.
However, none of these has reached clinical applicability yet.5Molecular Therapy: Methods & C
This is an open access article under the CC BY-NThe Gene-Switch (GS) regulated system, controlled by the synthetic
steroid mifepristone (Mfp), consists mainly of human peptides fused
together in the GS protein:6–10 (1) a truncated human progesterone
receptor that does not bind progesterone but Mfp, (2) a transcrip-
tional activation domain from human p65 of the NF-kB complex,
and (3) a short peptide of the yeast Gal4-DNA binding domain.
Mfp mediates dimerization of the GS protein, which then binds to
Gal4 target sites of a minimal promoter, thereby activating transcrip-
tion from this promoter and expression of the downstream transgene.
Interest in the GS was reinforced when it became clear that other
regulated gene therapy constructs are compromised by severe limita-
tions. The well-developed Tet-operon-based system proved to be
immunogenic in peripheral tissues of non-human primates
(NHPs), presumably due to its substantial content of bacteria-derived
components.11–13 Another promising system based solely on human
peptide components, the rapamycin-controlled dimerizer, lacks a
clinically approved alternative to the inducing drug rapamycin, which
is a strong immunosuppressant and crosses the blood-brain barrier
(BBB) only at a clinically unacceptable dose.14,15
We adopted the GS system for AAV vectors, aiming for a regulable
expression of the neurotrophic factor GDNF as a therapeutic option
to treat PD. This pre-clinical development resulted in a vector system
with excellent characteristics regarding high-level inducibility, with
negligible background and robust therapeutic efficacy in rodent
models of PD.16–18 Mfp is a US Food and Drug Administration
(FDA)-approved drug and thus readily available for clinical trials,
but we have found pronounced gender-specific differences in the
pharmacokinetics of Mfp.18 In addition, Mfp binds with high affinity
to a plasma carrier protein, a1-acid glycoprotein (AAG), only in hu-
man plasma and not in rodents19,20 or monkeys.21 If and to whichlinical Development Vol. 23 December 2021 ª 2021 The Authors. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Pharmacodynamics and -kinetics
depending on mifepristone formulation
(A) Schematic representation of the AAV-5-GS-GDNF
vector. ITR, inverted terminal repeat from AAV-2; GDNF,
glial cell line derived neurotrophic factor; WPRE, wood-
chuck hepatitis virus posttranscriptional regulatory
element; BGH, bovine growth hormone polyadenylation
site; SV40, simian virus 40 polyadenylation site; Int-a and
Int-b, synthetic introns; GS, fusion protein consisting of
Gal4 DNA binding domain, truncated human progester-
one receptor, and human p65 transactivation domain;
hSyn, 420 bp fragment of human synapsin 1 gene pro-
moter; TB, synthetic transcription blocker; UAS-TATA,
minimal TATA promoter with 6 upstream Gal4 binding
sites. (B) Schematic representation of the experimental
layout. 1  109 vg of AAV-5-GS-GDNF was injected
intracranially, and 3 weeks later Mfp was orally applied at
3  50 mg/kg in different formulations. Plasma samples
were collected at indicated time points; striatal tissue for
GDNF quantification was collected at t = 144 h after the
first Mfp application. (C) Striatal GDNF levels obtained
after oral application of various Mfp formulations. Pure
sub., pure substance of Mfp; Mifegyne, tablet formulation
ofMfp; Statistics by 1-way ANOVAwith Dunnett’s multiple
comparisons test. n.s., not significant; ****p < 0.0001; n =
5 animals per condition. (D) Plasma Mfp levels obtained at
time points indicated in (A) after oral application of 50 mg/
kg pure Mfp in ASV or Mifegyne in ASV. Statistics by 2-
way ANOVA with Sidak’s multiple comparisons test. **p <
0.01; ****p < 0.0001; n = 5 animals per condition.
Molecular Therapy: Methods & Clinical Developmentextent this binding affects the transport of Mfp over the blood-brain
barrier is currently unknown. Thus, a better understanding of Mfp’s
pharmacokinetics and -dynamics in terms of GDNF induction is ur-
gently needed. We accomplished this in a rat model expressing the
human AAG (hAAG) protein. Our data demonstrate that interaction
of Mfp with hAAG did not prevent activation of the GS-GDNF vector
in the brain and thus suggest that equivalent levels of GDNF can be
expected to be induced in human brain as compared to the brains
of experimental animals. We furthermore demonstrate that the
formulation of Mfp can significantly impact its pharmacodynamic
effectivity and that a clinically approved pharmacological booster, ri-
tonavir (Rtv), enhances the effect of Mfp by an order of magnitude,
both in rodents and non-human primates. As a cautionary note,
our data also suggest that individual pharmacokinetics of Mfp should
be taken into account for individual patients.
RESULTS
Different formulations of Mfp result in largely different
pharmacokinetics and -dynamics
Mfp is a synthetic steroid with very low solubility in water. Thus, in
our previous pre-clinical studies, we had used the compound mostly
dissolved in DMSO and applied by intraperitoneal (i.p.) injection.
However, oral application would be much preferred for use in pa-
tients. We therefore studied the pharmacodynamic effect of various
oral formulations of Mfp on induction of GS-controlled expression2 Molecular Therapy: Methods & Clinical Development Vol. 23 Decembof the neurotrophic factor GDNF. To this end, 2-month-old female
rats were intracranially injected with 1  109 vg of AAV-5-GS-
GDNF (Figure 1A), and 3 weeks later Mfp was orally applied on 3
consecutive days at 50 mg/kg (see Materials and methods for conver-
sion into human equivalent dosages) (Figure 1B). Mfp was used as
pure substance, which was either dissolved in EtOH, suspended in
sesame oil, or suspended in aqueous suspension vehicle (ASV). Alter-
natively, Mfp was used as the commercially available Mifegyne
formulation (200 mg/tablet), suspended in ASV. GDNF expression
in the brain (i.e., within the striatum, into which the vector had
been applied) was determined by ELISA at 4 days after the last Mfp
application.
Our results demonstrate that the solvent/carrier used for oral
administration had no influence on pharmacodynamics of Mfp in
brain tissue, as GDNF levels obtained were very similar after dis-
solving Mfp in EtOH or suspending it in sesame oil or ASV. How-
ever, the source of the drug had a profound influence on its phar-
macodynamics, in that the same dosage of Mifegyne, as compared
to the pure substance, resulted in 5-fold less activation of the GS
system as compared to the pure substance (Figure 1C). The reduced
bioavailability of Mifegyne was confirmed by substantially reduced
plasma Mfp levels (Figure 1D), with an area under the curve
(AUC) of 40,653 ± 3,352 ng/mL  h for the pure substance, and
22,181 ± 4,185 ng/mL  h for Mifegyne.er 2021
Figure 2. Cyp3A4 inhibition by ritonavir boosts
pharmacokinetics and -dynamics of Mfp
(A) Schematic representation of the experimental layout.
1  109 vg of AAV-5-GS-GDNF was injected intracrani-
ally, and 3 weeks later Mfp was applied i.p. with a co-
application of Rtv 20 min before Mfp application. Plasma
samples were collected at indicated time points; striatal
tissue for GDNF quantification was collected at t = 144 h
after the first Mfp application. In some animals, grapefruit
juice (GF) was given orally for 1 week before Mfp appli-
cation, as an alternative Cyp3A4 inhibitor. (B) Plasma
levels of Mfp in female rats after application of 3  5 mg/
kg Mfp i.p., without (black circles) and with (gray squares)
Rtv co-application. Statistics by 2-way ANOVA with Si-
dak’s multiple comparisons test. ***p < 0.001; ****p <
0.0001; n = 5 animals per condition. (C) Striatal GDNF
levels in female and male rats after application of 3 
5 mg/kg Mfp i.p., without (light gray bars) and with (dark
gray bars) co-application of Rtv. Note the split Y-scale.
Statistics by 1-way ANOVA with Dunnett’s test for multi-
ple comparisons. *p < 0.05; n = 5 animals per condition.
(D) Striatal GDNF level in female rats after application of
3 20 mg/kg Mfp i.p., without Rtv co-application ( Rtv),
with co-application of 30 mg/kg Rtv i.p. (+ Rtv i.p.), with
co-application of 30 mg/kg Rtv orally (+ Rtv oral), and with
co-application of 50% grapefruit juice (+ GF juice). Sta-
tistics by 1-way ANOVA with Dunnet’s test for multiple
comparisons. *p < 0.05; n = 3–5 animals per condition.
www.moleculartherapy.orgCyp3A4 inhibition robustly enhances the pharmacodynamic
response to Mfp
We have recently reported that Mfp exerts largely different pharma-
codynamics with respect to induction of GDNF expression in male
versus female rats.18 Thus, we sought to optimize the pharmacody-
namic properties of Mfp through temporal inhibition of Cyp3A4,
which is the liver cytochrome known to be primarily responsible
for degradation of Mfp.22 A suitable drug, which is both clinically
approved for this purpose and has an excellent safety profile, was
identified in Rtv, initially developed as an HIV protease inhibitor.23
In order to determine if Cyp3A4 is indeed responsible for gender-spe-
cific pharmacokinetics of Mfp and to elucidate if Cyp3A4 inhibition
can prevent this effect, we applied Rtv i.p. at 30 mg/kg, 20 min before
Mfp application (5 mg/kg, i.p.) on 3 consecutive days in male and fe-
male rats 2.5 months of age that had received striatal injection of
AAV-5-GS-GDNF 3 weeks earlier (Figure 2A). Plasma Mfp levels
were substantially elevated when Cyp3A4 activity was inhibited by
Rtv, andMfp persisted in plasma for about 2 days longer as compared
to application without Cyp3A4 inhibition (Figure 2B). The AUC for
plasma Mfp roughly tripled with Cyp3A4 inhibition ( Rtv = 8,197 ±
1,600 ng/mL  h; + Rtv = 27,813 ± 4,131 ng/mL  h; Figure 2B).
In both male and female rats, Rtv substantially enhanced pharmaco-
dynamics of Mfp: both genders showed GDNF levels of about 4,000
pg/mg tissue, as compared to about 350 pg/mg GDNF in females
and 100 pg/mgGDNF inmale rats that received onlyMfp (Figure 2C).
Thus, Rtv boosted GDNF induction about 10-fold in female rats andMolecular Tabout 40-fold in male rats. A second group of female rats that were
injected at 2 months of age with AAV-5-GS-GDNF was treated
with Mfp at a higher dosage of 20 mg/kg body weight, resulting in
striatal GDNF levels of about 2,000 pg/mg tissue without Rtv co-
application and in striatal GDNF levels of about 4,000 pg/mg tissue
after co-application of Rtv, which was given either i.p. or orally
(30 mg/kg) (Figure 2D). This experiment demonstrated that the
application route of Rtv does not affect its booster effect and that
GDNF levels of about 4,000 pg/mg tissue are likely to represent the
maximum capacity to synthesize the neurotrophic factor from the
AAV-5-GS-GDNF vector at the vector titer applied in these animals.
Notably, GDNF levels of about 100 pg/mg tissue have been shown to
be sufficient for a neurorestorative treatment regime in the partial
striatal 6-OHDA model of PD, if expressed for two relatively short
intermittent intervals starting 5 weeks after the 6-OHDA lesion was
induced.16
We also used a natural inhibitor of Cyp3A4, grapefruit juice,24 that
was given to female rats injected with AAV-5-GS-GDNF as a 50% so-
lution in water, for 7 days before application of Mfp (20 mg/kg, 3
i.p.). Intriguingly, grapefruit juice demonstrated the same potency
in boosting Mfp pharmacodynamics as Rtv, resulting in induced
striatal GDNF levels of about 4,000 pg/mg tissue (Figure 2D).
Mfp and Rtv act cooperatively in non-human primates
Wenext aimed to prove the pharmacokinetic boosting effect of Rtv on
Mfp plasma levels in an experimental animal model system as closely
related to humans as possible (i.e., NHPs). Large animal models areherapy: Methods & Clinical Development Vol. 23 December 2021 3
Figure 3. Rtv/Mfp co-application in non-human primates provides brain
Mfp levels sufficient for GS activation
(A) Plasma levels of Mfp in male cynomolgus monkeys after a single oral application
of 50 mg/kg Mfp alone (open circles) or co-application of 30 mg/kg Rtv with 50 mg/
kgMfp (black squares). (B) Plasma levels of Mfp after repeated oral co-application of
Rtv (60 mg/kg) with Mfp (100 mg/kg) in three individual monkeys (#1, #2, #3).
Statistics by unpaired Student’s t test for pairwise comparisons of AUCs. **p < 0.01;
****p < 0.0001. (C) Brain levels of Mfp after the repeated co-application scheme of
Rtv and Mfp as shown in (B). Statistics by 1-way ANOVA with Tukey’s test for
multiple comparisons. *p < 0.05; **p < 0.01.
Molecular Therapy: Methods & Clinical Developmentimportant to verify rodent-based data in animals of non-clonal origin,
as only these allow us to elucidate individual responses based on in-
dividual differences in drug absorption, distribution, and metabolism.
We also aimed to prove that in NHP Mfp reaches deep brain struc-
tures like the caudate/putamen (corresponding to the striatum in ro-
dents) in relevant amounts, as a pre-requisite to any therapeutic
application of GS-controlled GDNF expression in patients.
Three male cynomolgus monkeys were given 50 mg/kg Mfp with or
without prior application of 30 mg/kg Rtv. Both drugs were applied
through a naso-gastric probe in order to ensure optimal oral delivery.
Quantification of plasma Mfp levels clearly demonstrated that in the
monkeys Rtv exerted a comparable effect as in rodents (Figure 3A):
without Rtv, plasma Mfp levels reached 55 ng/mL, with an AUC of
655 ng/mL  h over the 24 h of sampling. Rtv co-application4 Molecular Therapy: Methods & Clinical Development Vol. 23 Decembincreased peak plasma levels of Mfp to 150 ng/mL, with an AUC of
2,651 ng/mL  h. However, we noted substantial variability in Mfp
plasma levels in both groups (note that error bars are given as SEM
instead of SD for the sake of clarity of presentation in Figure 3A), sug-
gesting that in NHPs individual differences in drug resorption, distri-
bution, and metabolism might be important to consider. Thus, in a
second experiment we co-applied higher dosages of Rtv (60 mg/kg)
and Mfp (100 mg/kg) on 3 consecutive days, hoping that this mode
of application would level out individual responses. Plasma Mfp
was quantified over time, and finally we quantified levels of Mfp in
different brain areas (Figures 3B and 3C). Monkeys #2 and #3 showed
a response, with plasmaMfp levels exceeding 500 ng/mL on all 3 days.
Monkey #1, however, reached this level only at the first day of Mfp
application, but not on the second and third days. Consequently,
we found significantly lower Mfp levels in the brain of this monkey
(Figure 3C). These findings suggest that individual differences in
resorption/distribution of Mfp may cause significantly different levels
of the compound in the brain. In any case, brain Mfp levels of about
0.5 ng/mg are sufficient to induce neuro-restorative levels of GDNF in
rodents (see Figure 5E), and thus even the lowest level of Rtv-aided
Mfp resorption/distribution seen in NHPs would be appropriate to
induce therapeutically active GDNF expression.
AAV-GS-GDNF is fully active in animals “humanized” for plasma
binding capabilities of Mfp
There is an important species-specific aspect that needs to be consid-
ered when attempting to transfer the GS from pre-clinical models to
humans: only in human plasma, but not in plasma of any other spe-
cies, including NHPs, Mfp is bound by a carrier protein, a1-acid
glycoprotein (AAG) or orosomucoid.25 Mfp-binding to hAAG signif-
icantly prolongs plasma half-life (T1/2 = 4 h in rats, 30 h in human)
and significantly reduces clearance (2.7 L/h/kg body weight in rats,
0.04 L/h/kg body weight in human).26 It is currently unknown if
Mfp binding to hAAG will impact pharmacodynamics of Mfp in
terms of GS-GDNF activation. On the one hand, binding of Mfp to
its carrier might sequester the steroid and thus prevent it from
crossing the blood-brain barrier in sufficient amounts to activate
GS-GDNF. If this would be the case, higher dosages of Mfp would
be necessary in humans, as was deduced from the rodent studies.
On the other hand, prolonged plasma half-life of hAAG-bound
Mfp might result in a longer-lasting release and delivery over the
blood-brain barrier, which might also result in higher levels of
GDNF induction.
As hAAG is mainly synthesized by hepatocytes and parenchymal cells
in the liver,27 we constructed an AAV-1/2 hybrid vector to express
hAAG from a liver-specific LP1 promoter.28 Intravenous application
of 1  1012 vg AAV-1/2-LP1-hAAG in 2-month-old female rats re-
sulted in sustained hAAG levels of about 0.4–0.5 mg/mL, which is
reasonably comparable to levels found in healthy humans (0.4–
0.6 mg/mL)29 (Figures 4A and 4B).
In order to prove that hAAG-expressing rats are functional in
terms of plasma Mfp binding, we applied Mfp either as a singleer 2021
Figure 4. Mfp plasma concentrations in hAAG-
humanized rats
(A) Schematic representation of the experimental layout.
AAV-LP1-hAAG was injected intravenously, and 4 and
8 weeks later plasma levels of hAAG were determined. In
animals with appropriate hAAG level, Mfp was applied
either orally once at 50 mg/kg or 3 i.p. at 5 mg/kg.
Plasma samples were taken at times indicated above the
arrow. (B) hAAG plasma levels obtained after i.v. injection
of AAV-1/2-LP1-hAAG vectors at titers of 1 1011 vg, 5
1011 vg, 10  1011 vg, and 20  1011 vg, determined at
1month (gray bars) and 2months (black bars) after vector
application. N = 4–5 animals per condition. (C) Mfp
plasma levels obtained in native (black circles) and hAAG-
expressing (open circles) rats after a single oral dose of
50 mg/kg Mfp. (D) Mfp plasma levels obtained in native
(black circles) and hAAG-expressing (open circles) rats
after a triple i.p. dose of 5 mg/kg Mfp. Statistics by 2-way
ANOVAwith Sidak’smultiple comparisons test. *p < 0.05;
**p < 0.01; ****p < 0.0001; n = 13 in (C) and 10 in (D).
www.moleculartherapy.orgoral dose of 50 mg/kg or as three consecutive i.p. doses of 5 mg/kg
and followed Mfp plasma levels in native and hAAG-expressing
rats. These data demonstrated that in hAAG-expressing rats,
Mfp persists considerably longer in plasma as compared to native
rats. After a single oral dose, Mfp plasma levels increased slower in
hAAG-expressing rats as compared to native rats, but while at 48 h
after application in native rats plasma Mfp levels had dropped by
over 80%, they were still at maximum level in hAAG-expressing
rats (Figure 4C). At 72 h after oral Mfp dosage, plasma levels in
hAAG-expressing rats were still at about one-third of maximum
levels, while Mfp was no longer detectable in plasma of native
rats. Repeated i.p. application of Mfp resulted in somewhat
different plasma pharmacokinetics of Mfp as compared to oral
application, in that early peak plasma levels were substantially
higher in hAAG-expressing rats as compared to native rats. Again,
plasma Mfp persisted significantly longer in hAAG-expressing
rats, where it was clearly detectable at 96 h and 120 h after the first
dosing (Figure 4D), while in native rats, plasma Mfp was no longer
detectable at these times. Thus, after both application schemes, we
found robustly prolonged plasma half-lives of Mfp in hAAG-ex-
pressing rats, suggesting that these animals mimic the human sit-
uation reasonably well.
In order to be able to compare results obtained in hAAG-expressing
rats with those of our previous studies in native rodents, we evaluated
pharmacodynamics of Mfp in terms of GS-GDNF activation by
applying Mfp at 3  5 mg/kg and 3  20 mg/kg i.p., both in
hAAG-expressing and native animals (Figure 5A). As shown in Fig-
ure 2B, application of 3  5 mg/kg Mfp i.p. results in peak plasma
levels of about 150 ng/mL, corresponding to about 0.3 mMofMfp. Af-
ter i.p. application of 3  20 mg/kg, we had determined peak plasma
levels of about 750 ng/mL in an earlier study (see Figure 4C in Cheng
et al.18), corresponding to 1.9 mMMfp. These concentrations are well
within the range where Mfp is bound by human plasma protein to anMolecular Textent of >98%,30 ensuring that the conditions applied are as similar
as possible to the human situation.
As shown in Figure 5B, plasma Mfp levels were significantly elevated
at 50 h and especially at 72 h in hAAG-expressing animals as
compared to native animals, after 3  20 mg/kg Mfp. Striatal
GDNF levels were similar in both animal groups, indicating that
hAAG binding of Mfp did not impact its capability to cross the
blood-brain barrier and to induce GS-GDNF. Using the lower dosage
of 3 5 mg/kgMfp also showed no negative effect on GS-GDNF acti-
vation (Figure 5D), indicating that at both dosages the presence of the
plasma carrier of Mfp did not influence its pharmacodynamics in
terms of GS-GDNF activation. Equal GDNF levels in native and
hAAG-expressing animals corresponded well with equal Mfp levels
in their brain tissue (Figure 5E).
Aging robustly affects the pharmacodynamic effect of Mfp on
the GS-GDNF vector
Finally, we addressed the effect of aging on pharmacodynamics of
Mfp with respect to induction of GDNF expression in the brain. To
this end, we expressed GS-GDNF in female and male rats 2 months
of age and in female and male rats 15 months of age. As shown in Fig-
ure 6, induced levels of GDNF were about 7–8 times higher in aged
animals as compared to young animals, in both genders. These data
suggest that bioavailability of Mfp depends dramatically on the age
of the subject, at least in rodents.
DISCUSSION
The compound used to control a regulable vector is probably the most
import single player in the whole system. It must be clinically
approved, devoid of side effects, preferably orally available, allow
for decent induction of gene expression, and, in the case of gene ther-
apy for brain diseases, must cross the blood-brain barrier at accept-
able dosages. Furthermore, the compound should exert itsherapy: Methods & Clinical Development Vol. 23 December 2021 5
Figure 5. Pharmacokinetics and -dynamics ofMfp in
hAAG-humanized rats
(A) Schematic representation of the experimental layout.
Simultaneously, 1  109 vg of AAV-GS-GDNF was in-
jected intracranially and 1  1012 vg AAV-LP1-hAAG was
injected i.v. Three weeks later hAAG levels were
confirmed and Mfp was applied 3 i.p. at either 5 mg/kg
or 20 mg/kg at the indicated times. Plasma samples were
taken at times indicated above the arrow. (B) Plasma
levels of Mfp after application of 3  20 mg/kg, in native
(light gray bars) and hAAG-humanized rats (dark gray
bars). For this experiment, plasma samples were taken
only at 50 h and 72 h. Statistics by 1-way ANOVA with
Sidak’s test for multiple comparisons. **p < 0.01; ***p <
0.001; n = 6 animals per condition. (C) Striatal GDNF
levels after application of 3 20mg/kgMfp, in native (light
gray bars) and hAAG-humanized rats (dark gray bars).
Statistics by two-tailed, unpaired t test. n.s., not signifi-
cant. N = 5 animals per condition. (D) Striatal GDNF levels
after application of 3  5 mg/kg Mfp, in native (light gray
bars) and hAAG-humanized rats (dark gray bars). Statis-
tics by two-tailed, unpaired t test. n.s., not significant. n =
3 animals per condition. (E) Brain tissue levels of Mfp after
application of 3  20 mg/kg, i.p., in native animals (left)
and hAAG-humanized rats (right). Mfp levels were determined at t = 144 h (i.e., at the same time when GDNF levels were determined in brain tissue). Cx, cortex; Str, striatum;
Cer, cerebellum. Statistics by 1-way ANOVA with Tukey’s test for multiple comparisons. n = 5 animals per condition.
Molecular Therapy: Methods & Clinical Developmentpharmacodynamic effect over a certain range of dosages in order to
allow for adjustments to individual patient’s needs. While Mfp has
demonstrated many of these features, considerable issues remained
to be addressed. The fact that Mfp had been developed as an emer-
gency contraceptive for younger females may explain the substantial
lack of pharmacological data for males and older individuals and for
CNS applications in general.
1. Origin of Mfp: while our data demonstrate that Mfp can be given in
various oral formulations, they also show that the pure substance
seems to be absorbed far better than the commercially available Mi-
fegyne formulation. Thus, application of the pure substance may
allow use of lower dosages or induce higher levels of GDNF in PD
patients.
2. Cyp3A4 inhibition: our data unequivocally demonstrate that
gender-specific pharmacokinetic differences of Mfp can be resolved
by inhibition of its major degradation pathway through cytochrome
P430 3A4. Furthermore, the pharmacodynamic effect of Mfp in terms
of GDNF induction can be substantially boosted by Cyp3A4 inhibi-
tion through Rtv. Actually, Rtv is in clinical use mainly due to its
robust inhibitory effect on Cyp3A4,31,32 as an adjunct therapy for
HIV protease inhibitors,33 but also for treatment of hepatitis C virus
infections,34 with a well-acceptable safety profile. However, metabolic
effects of Rtv, such as a moderate increase in insulin resistance,35
should be monitored, even after the infrequent co-application of
Rtv with Mfp, as considered for activation of the GS.
Side effects even after long-term daily use of high doses of Mfp, due to
its binding to progesterone and glucocorticoid receptors, are only6 Molecular Therapy: Methods & Clinical Development Vol. 23 Decembvery mild (reversible asthenia and rashes).26 Human equivalent doses
(HEDs) exceeding those of 50 mg/kg in rodents have been safely
applied for 14 consecutive days in males,36 and HEDs exceeding
20 mg/kg in rats have been safely applied to males and non-pregnant
women daily for several months.37,38
For a continuous activation of GDNF production, we consider a
monthly application of Mfp on 3 consecutive days to be sufficient,16,18
but even in this case, co-dosage with Rtv may allow use of dosages of
Mfp that are completely devoid of any potential side effects. Alterna-
tively, Rtv may be exploited to induce maximal levels of GDNF: the
dynamic range of the AAV-5-GS-GDNF vector appears to be
extremely wide, reaching from zero non-induced background16,18
to induced levels of about 700-fold over that of the endogenous rat
brain GDNF levels of 5–6 pg/mg tissue, if Rtv is used as a booster
drug. This potency of induction may be used in a way that high levels
of GDNF are triggered in initial treatment stages, in order to initiate
resprouting of dopaminergic innervation in the basal ganglia, while
much lower levels of GDNF would be induced in later stages of treat-
ment, in order to prevent side effects.
However, our results obtained with Cyp3A4 inhibition by grapefruit
juice also suggest that care must be taken to avoid excessive levels of
AAV-GS-GDNF activation by nutritional components like
furanocumarins.39
3. Individual pharmacokinetics forMfp inNHP: theNHPdatagenerally
suggest that Rtv-boostedMfp pharmacodynamics will also be available
in patients. However, the NHP data also suggest that individual differ-
ences in Mfp pharmacokinetics and -dynamics might be important toer 2021
Figure 6. Impact of aging on pharmacodynamics of Mfp
(A) Schematic representation of the experimental layout. 1  109 vg of AAV-5-GS-
GDNF were injected intracranially, and 3 weeks later Mfp was applied i.p. at 3 
20 mg/kg. Striatal tissue for GDNF quantification was collected at t = 144 h. (B)
Striatal GDNF levels in young female and male rats 2 months of age (solid bars) and
in aged female and male rats 15 months of age (hatched bars). Note the split Y-
scale. (C) Statistical evaluation by 1-way ANOVA with Tukey’s test for multiple
comparisons. n.s = not significant; ****p < 0.0001; n = 7 animals each 2 months of
age, and 4 animals each 15 months of age.
www.moleculartherapy.orgconsider. Despite the small group size, substantially different levels of
Mfp were achieved in the brain of monkey #1 versus brains of monkeys
#2 and#3.While the repeated application scheme seems to level someof
the different individual responses to Mfp dosage, a 6- to 7-fold differ-
ence in brain Mfp levels after the same dosage cannot be neglected.
Thus, it may be advisable to determine a basic pharmacokinetic for
Mfp in individual patients before treating them with the AAV-GS-
GDNF vector, in order to ensure induction of similar levels of GDNF.
4. Human-specific interaction of Mfp with a1-acid glycoprotein:
hAAG (also called orosomucoid) is expressed in humans by two
closely related genes, ORM1 and ORM2, which, due to polymor-
phisms, give rise to several alleles that differ significantly in their ca-
pabilities to bind Mfp. In general, ORM2-derived AAG variants bind
Mfp only weakly, while some ORM1-derived variants (ORM1F1 and
ORM1S) are able to bind Mfp with high affinity, and others
(ORM1F2) have only low affinity.25,40,41 No gender-related differ-
ences in the ORM genes are known.42 For our study, we expressed
the S-variant of hAAG (arginine at amino acid position 20 and valine
at amino acid position 156). While this variant alone does not repre-
sent the full spectrum of possible interactions of Mfp with human
plasma carrier proteins, it can be considered representative for the
high-affinity interaction of hAAG with Mfp. From our data, we
conclude that there are no principal hurdles for the application of
Mfp to tightly control GDNF expression from the GS vector in pa-
tients, given that in the absence and presence of hAAG the induced
GDNF levels were almost identical.Molecular T5. Aging: the robust impact of aging on pharmacodynamics of Mfp
might be interpreted in two controversial ways: on the one hand,
this fact can be interpreted as favorable, since it can be anticipated
that for the aged parkinsonian patients to be treated by gene therapy
with AAV-GS-GDNF, even lower dosages of Mfp (alone or in com-
bination with Rtv) may be used, thereby bypassing any risk of side ef-
fects caused by application of these drugs. On the other hand, it ap-
pears to be necessary to pre-screen putative recipients of this
therapy for their Mfp plasma (or probably cerebrospinal fluid) levels
after application of oral dosages, as was already suggested by the
evident variability of Mfp pharmacokinetics in non-human primates.
It is not trivial to define a reason for the substantial effect of age on
Mfp pharmacodynamics, and it is currently uncertain if it can be fully
translated to the human situation. For aged rodents, a significant
reduction of Cyp3A (but not specifically Cyp3A4) has been re-
ported,43 which may at least partially explain the much higher levels
of GDNF induced in aged rats. However, in human liver microsomes,
Cyp3A4 activity was not affected by aging44,45 and thus may not
impact Mfp pharmacokinetics. Nonetheless, aged individuals present
with significant alterations in hepatic size and blood flow, an
increased distribution volume for lipophilic drugs like Mfp in fat tis-
sue, a generally increased interindividual variability in drug disposi-
tion,45 and probably also with a less-restrictive blood-brain barrier,
all of which might impact Mfp pharmacokinetics and -dynamics.
Moreover, turnover rates of GDNF in brain tissue may be influenced
by aging. As such, definition of human dosages of Mfp for a fine-




The recombinant AAV-5 vector expressing the GS under control of
the neuron-specific synapsin 1 gene promoter and GDNF from the
inducible UAS-TATA promoter (Figure 1A) has been described in
detail elsewhere.16,18 The AAV-1/2-LP1-hAAG vector expressing
hAAG uses a liver-specific LP1 promoter28 to express the high-affin-
ity S-variant of hAAG,40,46 which binds Mfp specifically in human
plasma.25 The vector was packaged into a hybrid AAV-1/2 capsid
for enhanced liver tropism.47 Of note, vectors exploiting a chicken-
beta actin promoter or an AAV-8 capsid did not succeed in long-
term expression of hAAG in rats, probably due to immunological
clearance of transduced cells. Vectors were packaged in transiently
transfected HEK293 cells and purified from cell lysates by iodixanol
gradient ultracentrifugation and fast protein liquid chromatography
(FPLC) heparin (AAV-1/2) or AVB Sepharose (AAV-5) affinity
chromatography.
Animal surgery
All animal experiments were conducted according to approved exper-
imental animal licenses (16/2074 and 19/3117) issued by the respon-
sible animal welfare authority (Niedersächsisches Landesamt für Ver-
braucherschutz und Lebensmittelsicherheit, LAVES) and controlled
by the local animal welfare committee and veterinarians of Universityherapy: Methods & Clinical Development Vol. 23 December 2021 7
Molecular Therapy: Methods & Clinical DevelopmentMedical Center Göttingen and Charles River Laboratories Germany,
Göttingen.
Stereotaxic injection of the AAV-5-GS-GDNF vector into the left
striatum ofWistar rats was performed under ketamine/xylazine anes-
thesia exactly as described.16 AAV-1/2-LP1-hAAGwas injected intra-
venously (i.v.) through the tail vein at times of intracranial injection of
AAV-5-GS-GDNF. Blood samples of about 250 mL were collected
from the tail vein into KE3 type Sarstedt tubes including 1.6 mg
EDTA/mL, centrifuged for 10min at 4C and 10,000 rpm, and plasma
was stored at 20C until use. Mfp and Rtv were applied orally by
gavage or injected i.p. in volumes of 1 mL/kg body weight.
Three experimentally non-naive, male cynomolgus macaques
(Macaca fascicularis) of Chinese origin, aged 3–4 years were used
for NHP experiments. Animals were group-housed in group cages
in a climate-controlled room with a 12-h light 12-h dark cycle. The
temperature and relative humidity ranges were 22.5C–25.5C and
40%–70%, respectively. Water was available ad libitum. Animals
were provided daily with sufficient meals of balanced composition
providing sufficient gross nutrients. In addition, fresh fruit or vegeta-
bles were provided daily as a food supplement.
Mfp (t = 0) and Rtv (t =1 h) were applied orally using a nasogastric
tube (10 mL per compound) at a single dose (Mfp: 50 mg/kg, Rtv:
30 mg/kg), or a repeated dose (Mfp: 100 mg/kg, Rtv: 60 mg/kg,
once daily for 3 days), as described in Figure 3. Due to training in pre-
vious experiments, the animals were used to sitting in a subject chair
for the duration of the experiment, so that blood sampling and appli-
cation of the substances could be done without anesthesia. Finally, an-
imals were anaesthetized by intramuscular (i.m.) application of keta-
mine (10 mg/kg), and xylazine (0.05 mg/kg) and sacrificed by a
pentobarbital overdose (>50 mg/mL) i.v. Animals were intracardially
perfused with ice-cold PBS, and the brain was removed for analysis.
Drugs
Mfp was obtained as pure substance from Sigma (M8046) or as tablet
formulation Mifegyne (200 mg/tablet; Mfp content confirmed by
high-performance liquid chromatography [HPLC] with diode array
detection, see below) from Nordic Pharma. Rtv was obtained from
AbbVie as Norvir 100 mg. Mfp and Rtv were either diluted in
DMSO for i.p. application or suspended in ASV (0.9% NaCl [w/v],
0.5% carboxymethyl-cellulose MW 250.000 [w/v], 0.4% polysorbate
80 [v/v], 0.9% benzyl alcohol [v/v]). Mfp was also used as suspension
in sesame oil.
Drug dosages applied to rats and monkeys can be converted to HEDs
according to the FDA-approved body surface area (BSA) normaliza-
tion approach.48,49 Specifically, calculating HEDðmg =kgÞ=
animal doseðmg =kgÞxðanimal weight kg=human weight kgÞ10:67
results in the following conversion factors: for rats weighing 250 g,
monkeys weighing 3 kg, and an assumed human weight of 70 kg:
rat dosage (e.g., 50 mg/kg)  0.156 = HED (7.8 mg/kg); monkey
dosage (e.g., 50 mg/kg)  0.357 = HED (17.9 mg/kg). In addition,8 Molecular Therapy: Methods & Clinical Development Vol. 23 Decembit must be considered that bioavailability of Mfp in monkeys (15%)
is considerably lower compared to humans and rats (40%),19 justi-
fying higher dosages to be applied in monkeys as compared to rats.hAAG and GDNF ELISAs
For quantification of hAAG levels in plasma samples, the hAAG
ELISA R&D DY3694 was used exactly as specified by the manufac-
turer. Quantification of striatal GDNF levels was performed essen-
tially as described.16
Quantification of Mfp from plasma and tissue samples
Quantification of Mfp from plasma samples was performed by HPLC
on an Ultimate 3000 system equipped with C18-RP column (5 mm,
120 Å, 2.1  250 mm, mobile phase 25% methanol, 47% acetonitrile,
28% water) and diode array detection (304 nm for Mfp, 254 nm for
the internal standard loratadine) or ISQ EC single quadrupole mass
spectrometry detection. For liquid-liquid extraction, a 50 mL plasma
sample was mixed with 5 mL 10% acetic acid, 100 mL methanol,
5 mL 1 mg/mL loratadine, and 1 mL ethyl acetate. After vortexing
for 20 s and centrifugation at 10,000 rpm for 5 min at room temper-
ature (RT), the supernatant was transferred to a new tube. The pellet
was reextracted with the same procedure and the combined superna-
tants dried down under vacuum. The sample was reconstituted in
50 mL methanol and loaded onto the HPLC.
Tissue samples were snap frozen on dry ice, then lysed by mechanical
disruption with 1.4 mm zirconium beads in a Precellys tissue homog-
enizer in the same organic extraction solution as described for plasma
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